Every 424B that Quoin Pharmaceuticals, Ltd. (QNRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow QNRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full QNRX filings page.
Quoin Pharmaceuticals Ltd. (QNRX) registered for resale up to 9,371,895 ADSs representing 328,016,325 ordinary shares held by selling shareholders; Quoin is not selling ADSs in this prospectus. Selling shareholders receive resale proceeds. Quoin will not receive proceeds from those sales, but could receive up to approximately $19.1 million, less placement agent fees, if all Ordinary Warrants are exercised for cash.
The private placement closed on August 31, 2026, with approximately $30.8 million in gross proceeds and approximately $29.0 million in net proceeds. ADSs covered but not currently outstanding represent approximately 144.2% of the 4,804,161 ADSs outstanding as of September 16, 2026; Quoin says actual issuance may be less than the amount registered. Ordinary Warrants have a $6.10-per-ADS exercise price and expire at the earlier of five years from closing or 30 days after public announcement that the QRX003-004 trial's primary endpoint has been met. The incorporated 2025 audit report includes an explanatory paragraph concerning Quoin's ability to continue as a going concern.
Quoin Pharmaceuticals Ltd. updates its resale prospectus supplement to reflect a substitution in the Selling Shareholders table and the transfer of warrants tied to ADSs. The registration covers 10,045,455 American Depositary Shares (ADSs) representing 351,590,925 ordinary shares.
The supplement substitutes SILV Fund Ltd. for Point72 Associates, LLC for a transferred block of warrants to purchase 909,090 ADSs; the prospectus remains otherwise unchanged. The ADSs trade on Nasdaq under the symbol QNRX.
Quoin Pharmaceuticals Ltd. is registering up to 10,045,455 American Depositary Shares (ADSs) for resale by investors who participated in an October 2025 private placement.
These ADSs include shares already issued and shares underlying pre-funded and ordinary warrants, and the company states that issuing all of them could significantly increase the ADSs in the public market. The ADSs covered by this prospectus that are not currently outstanding, including 1,968,939 Pre-Funded ADSs and 8,036,364 Ordinary Warrant ADSs, represent approximately 1,193% of the 838,976 ADSs outstanding as of November 3, 2025, so existing holders could experience substantial dilution.
Quoin will not receive proceeds from shareholder resales, but it could receive up to $88.7 million if all Ordinary Warrants are exercised for cash, which it plans to use for general corporate purposes, including advancing its rare-disease pipeline led by QRX003 for Netherton Syndrome and related orphan-designated programs.